Christopher Pierce Prelude Therapeutics Inc (PRLD) insider trading activity

Christopher Pierce is EVP and Chief of Business Oper of Prelude Therapeutics Inc. Currently has a direct ownership of 3,750 shares of PRLD, which is worth approximately $4,500. The most recent transaction as insider was on Sep 02, 2021, when has been sold 17,000 shares (Common Stock) at a price of $41.44 per share, resulting in proceeds of $704,480. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 3.75K

0% 3M change

0% 12M change

Total Value Held $4,500

Christopher Pierce Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 02 2021	SELL Open market or private sale	$704,480 $41.44 p/Share	17,000 Reduced 81.93%	3,750 Common Stock
Sep 02 2021	BUY Exercise of conversion of derivative security	$218,450 $12.85 p/Share	17,000 Added 45.03%	20,750 Common Stock
Apr 29 2021	SELL Open market or private sale	$132,756 $40.29 p/Share	3,295 Reduced 46.77%	3,750 Common Stock
Apr 29 2021	BUY Exercise of conversion of derivative security	$6,228 $1.89 p/Share	3,295 Added 31.87%	7,045 Common Stock
Apr 08 2021	SELL Open market or private sale	$8,000 $40.0 p/Share	200 Reduced 5.06%	3,750 Common Stock
Apr 08 2021	BUY Grant, award, or other acquisition	$378 $1.89 p/Share	200 Added 4.82%	3,950 Common Stock
Apr 07 2021	SELL Open market or private sale	$33,186 $40.08 p/Share	828 Reduced 18.09%	3,750 Common Stock
Apr 07 2021	BUY Grant, award, or other acquisition	$1,565 $1.89 p/Share	828 Added 15.32%	4,578 Common Stock

Christopher Pierce

EVP and Chief of Business Oper

Wilmington, DE

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PRLD shares.

Notify only if

Value

Insider Trading

Get notified when an Prelude Therapeutics Inc insider buys or sells PRLD shares.

Notify only if

Operation

Value

Type

News

Receive news related to Prelude Therapeutics Inc

Track Activities on PRLD

Account